Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period ended September 30, 2022. The report, dated October 25, 2022, serves to furnish the Company's Appendix 4C Quarterly Cashflow Report released to the Australian Securities Exchange (ASX) to U.S. investors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached Exhibit 99.1 (Quarterly Report for the Period Ended September 2022), which is referenced but not detailed in the body of this Form 6-K.
Material Changes
The filing text does not provide data to compare current period performance against prior comparable periods. No material changes are described in the summary text of this document.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document functions solely as a conduit for the ASX quarterly cashflow report.
Investor Verification Checklist
- Verify the correct registrant name is Bionomics Limited, not Neuphoria Therapeutics Inc.
- Review Exhibit 99.1 (Appendix 4C) for actual cash flow figures and financial position details.
- Confirm the reporting period is the quarter ended September 30, 2022.
- Check the ASX announcement dated October 25, 2022, for the full context of the cashflow report.